AVXL (Anavex Life Sciences) Shares Outstanding (Diluted Average) : 84.54 Mil (As of Jun. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Anavex Life Sciences Shares Outstanding (Diluted Average)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Anavex Life Sciences's average diluted shares outstanding for the quarter that ended in Jun. 2024 was 84.54 Mil.

Anavex Life Sciences Shares Outstanding (Diluted Average) Historical Data

The historical data trend for Anavex Life Sciences's Shares Outstanding (Diluted Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anavex Life Sciences Shares Outstanding (Diluted Average) Chart

Anavex Life Sciences Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Shares Outstanding (Diluted Average)

Get a 7-Day Free Trial

48.91

58.20

69.80

76.91

79.79

Anavex Life Sciences Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Shares Outstanding (Diluted Average)	Get a 7-Day Free Trial															80.88	82.00	82.08	82.46	84.54

Anavex Life Sciences Shares Outstanding (Diluted Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

Anavex Life Sciences (NAS:AVXL) Shares Outstanding (Diluted Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.

Anavex Life Sciences Shares Outstanding (Diluted Average) Related Terms

Thank you for viewing the detailed overview of Anavex Life Sciences's Shares Outstanding (Diluted Average) provided by GuruFocus.com. Please click on the following links to see related term pages.

Anavex Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anavex Life Sciences Corp (NAS:AVXL) » Definitions » Shares Outstanding (Diluted Average)

Comparable Companies

Traded in Other Exchanges

0HFR:UK 12X1:Germany 12X1:Germany

Address

630 5th Avenue, 20th Floor, New York, NY, USA, 10111

Website

https://www.anavex.com

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.

Executives

Donhauser Peter D.o.	director	REGINA-KIRCHMAIER STRASSE 4, KAUFBEUREN 2M 87600
Steffen Thomas	director	FALLMERAYER STR. 19, MUNICH 2M 80796
Christopher U Missling	director, officer: President, CEO, CFO, Treasurer, other: Secretary	61 MOULTON ST, CAMBRIDGE MA 02138
Athanasios Skarpelos	10 percent owner	14,RUE KLEBERG, GENEVA V8 CH-1201
Jiong Ma	director	445 PARK AVENUE, 9TH FLOOR, NEW YORK NY 10022
Elliot Favus	director	51 W 52ND STREET, 7TH FLOOR, NEW YORK NY 10091
Sandra Boenisch	officer: PFO & Treasurer	51 WEST 52ND STREET, 7TH FLOOR, NEW YORK NY 10019
Claus Vander Velden	director	PO BOX MUENSTEREIFELER ST., COLOGNE 2M 50937
Bernd Metzner	director	51 W 52ND STREET, 7TH FLOOR, NEW YORK NY 10019
George F Tidmarsh	director, officer: Executive Director
John Robert Chisholm	director	16308 36A AVENUE, SURREY A1 V3S 0X5
William Sean Lowry	director	1172 BAY STREET, SUITE 300, ONTARIO Z4 M5S1L9
David L. Tousley	director	14610 PAWNEE LANE, LEAWOOD KS 66224
Harvey Lalach	director, officer: President CEO CFO	4837 CANYON RIDGE CRESENT, KELOWNA A1 V1W 4A1
Alison E. Ayers	director	27 O'CONNOR CIRCLE, WEST ORANGE NJ 07052